ASP Isotopes Inc. $ASPI is Philadelphia Financial Management of San Francisco LLC's 8th Largest Position

Key Points

• Philadelphia Financial Management of San Francisco LLC increased its stake in ASP Isotopes Inc. by 11.2%, making it the firm's 8th largest position, valued at approximately $16.45 million.
• ASP Isotopes recently reported a significant earnings miss, with a net loss of ($1.03) earnings per share against an expected loss of ($0.11), while revenue was $1.20 million, below the anticipated $1.60 million.
• Two analysts upgraded their ratings for \"ASP Isotopes Inc.\", with Canaccord Genuity raising the target price from $8.50 to $11.00 and giving it a "buy" rating.

Philadelphia Financial Management of San Francisco LLC lifted its holdings in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 11.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,508,062 shares of the company's stock after purchasing an additional 354,517 shares during the period. ASP Isotopes accounts for 3.2% of Philadelphia Financial Management of San Francisco LLC's holdings, making the stock its 8th biggest holding. Philadelphia Financial Management of San Francisco LLC owned about 4.67% of ASP Isotopes worth $16,453,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in shares of ASP Isotopes in the fourth quarter valued at about $34,000. SBI Securities Co. Ltd. boosted its position in ASP Isotopes by 84.8% during the first quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after acquiring an additional 4,299 shares during the last quarter. Millennium Management LLC acquired a new stake in ASP Isotopes during the 4th quarter worth about $55,000. Fortitude Advisory Group L.L.C. acquired a new position in shares of ASP Isotopes in the 1st quarter valued at about $64,000. Finally, ProShare Advisors LLC acquired a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $67,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $7.75.

Insider Activity

In related news, CEO Paul Elliot Mann sold 81,077 shares of the business's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $8.39, for a total transaction of $680,236.03. Following the sale, the chief executive officer directly owned 8,084,191 shares in the company, valued at approximately $67,826,362.49. The trade was a 0.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Duncan Moore sold 75,000 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $9.28, for a total value of $696,000.00. Following the sale, the director directly owned 994,553 shares in the company, valued at $9,229,451.84. This trade represents a 7.01% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 245,591 shares of company stock worth $2,139,790. 21.40% of the stock is owned by corporate insiders.

ASP Isotopes Stock Performance

NASDAQ:ASPI traded up $0.56 during trading hours on Thursday, reaching $8.93. The stock had a trading volume of 2,209,470 shares, compared to its average volume of 3,210,229. ASP Isotopes Inc. has a 12-month low of $2.50 and a 12-month high of $11.68. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. The stock has a 50 day simple moving average of $9.08 and a 200 day simple moving average of $7.09. The stock has a market cap of $820.76 million, a P/E ratio of -14.62 and a beta of 3.35.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The firm had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.60 million. On average, research analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.